1. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
- Author
-
Jennings, Danna, primary, Huntwork-Rodriguez, Sarah, additional, Henry, Anastasia G., additional, Sasaki, Jennifer C., additional, Meisner, René, additional, Diaz, Dolores, additional, Solanoy, Hilda, additional, Wang, Xiang, additional, Negrou, Elvira, additional, Bondar, Vitaliy V., additional, Ghosh, Rajarshi, additional, Maloney, Michael T., additional, Propson, Nicholas E., additional, Zhu, Yuda, additional, Maciuca, Romeo D., additional, Harris, Laura, additional, Kay, Angela, additional, LeWitt, Peter, additional, King, T. Alex, additional, Kern, Drew, additional, Ellenbogen, Aaron, additional, Goodman, Ira, additional, Siderowf, Andrew, additional, Aldred, Jason, additional, Omidvar, Omid, additional, Masoud, Shababa T., additional, Davis, Sonnet S., additional, Arguello, Annie, additional, Estrada, Anthony A., additional, de Vicente, Javier, additional, Sweeney, Zachary K., additional, Astarita, Giuseppe, additional, Borin, Marie T., additional, Wong, Bradley K., additional, Wong, Harvey, additional, Nguyen, Hoang, additional, Scearce-Levie, Kimberly, additional, Ho, Carole, additional, and Troyer, Matthew D., additional
- Published
- 2022
- Full Text
- View/download PDF